Literature DB >> 8494369

In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A).

B P Goldstein1, M Berti, F Ripamonti, A Resconi, R Scotti, M Denaro.   

Abstract

MDL 62,879 (GE2270 A) is a new peptide antibiotic that inhibits protein synthesis through an interaction with elongation factor Tu. MDL 62,879 was very active against gram-positive clinical isolates, particularly staphylococci and enterococci, for which MICs for 90% of isolates were < or = 0.13 micrograms/ml. It was equally active against isolates resistant to beta-lactams, erythromycin, gentamicin, and glycopeptides. It also had activity against Mycobacterium tuberculosis. MDL 62,879 had moderate bactericidal activity against staphylococci.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8494369      PMCID： PMC187747          DOI： 10.1128/AAC.37.4.741

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

2.  Vancomycin-resistant bacteria.

Authors:  D M Shlaes
Journal:  Infect Control Hosp Epidemiol       Date:  1992-04       Impact factor: 3.254

3.  Methicillin-resistant Staphylococcus aureus--a reappraisal.

Authors:  C T Keane; D C Coleman; M T Cafferkey
Journal:  J Hosp Infect       Date:  1991-11       Impact factor: 3.926

4.  Mutations of Bacteria from Virus Sensitivity to Virus Resistance.

Authors:  S E Luria; M Delbrück
Journal:  Genetics       Date:  1943-11       Impact factor: 4.562

5.  Antibiotic GE2270 a: a novel inhibitor of bacterial protein synthesis. I. Isolation and characterization.

Authors:  E Selva; G Beretta; N Montanini; G S Saddler; L Gastaldo; P Ferrari; R Lorenzetti; P Landini; F Ripamonti; B P Goldstein
Journal:  J Antibiot (Tokyo)       Date:  1991-07       Impact factor: 2.649

6.  Inhibition of bacterial protein synthesis by elongation-factor-Tu-binding antibiotics MDL 62,879 and efrotomycin.

Authors:  P Landini; M Bandera; B P Goldstein; F Ripamonti; A Soffientini; K Islam; M Denaro
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

7.  In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteria.

Authors:  A King; L Bethune; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  New antibiotic that acts specifically on the GTP-bound form of elongation factor Tu.

Authors:  P H Anborgh; A Parmeggiani
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598
  8 in total
  9 in total

1.  Antibiotic production improvement in the rare actinomycete Planobispora rosea by selection of mutants resistant to the aminoglycosides streptomycin and gentamycin and to rifamycin.

Authors:  Fabrizio Beltrametti; Roberta Rossi; Enrico Selva; Flavia Marinelli
Journal:  J Ind Microbiol Biotechnol       Date:  2005-12-06       Impact factor: 3.346

2.  In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteria.

Authors:  A King; L Bethune; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

3.  Increasing problems in the therapy of enterococcal infections.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

4.  Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.

Authors:  Diane M Citron; Kerin L Tyrrell; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

5.  In vitro and in vivo activities of novel, semisynthetic thiopeptide inhibitors of bacterial elongation factor Tu.

Authors:  J A Leeds; M J LaMarche; J T Brewer; S M Bushell; G Deng; J M Dewhurst; J Dzink-Fox; E Gangl; A Jain; L Lee; M Lilly; K Manni; S Mullin; G Neckermann; C Osborne; D Palestrant; M A Patane; A Raimondi; S Ranjitkar; E M Rann; M Sachdeva; J Shao; S Tiamfook; L Whitehead; D Yu
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 6.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

7.  A Derivative of the Thiopeptide GE2270A Highly Selective against Propionibacterium acnes.

Authors:  Attilio Fabbretti; Cheng-Guang He; Eleonora Gaspari; Sonia Maffioli; Letizia Brandi; Roberto Spurio; Margherita Sosio; Daniela Jabes; Stefano Donadio
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

8.  In vitro activity of MDL 62,879 against gram-positive bacteria and Bacteroides species.

Authors:  A Bartoloni; A Mantella; B P Goldstein; M Denaro; P Nicoletti; F Paradisi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

Review 9.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.